Zontivity Coupons & Savings Card – Discount Prices from $399.51
My prescription
Edit
2.08MG, Zontivity (30 Tablets)
Select pharmacy
CVS
$421.53
COUPON PRICE
Walmart
$399.51
COUPON PRICE
Walgreens
$410.50
COUPON PRICE
Albertsons
$424.09
COUPON PRICEZontivity savings card
Show this card to your pharmacistWalmart
$399.51
BIN
ID
PCN
GRP
019876
LHD06C4624
CHIPPO
LHX
Powered by
Related antiplatelet drugs prescriptions
More prescriptions for stroke risk reduction
Related antiplatelet drugs prescriptions
More prescriptions for stroke risk reduction
Price history for Zontivity
30 Tablets, 2.08MG
Average retail price for Zontivity
Average SaveHealth price for Zontivity
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Zontivity dosage forms
Dosage Quantity Price from Per unit 2.08MG 30 Tablets $399.51 $13.32 2.08MG 90 Tablets $1,236.52 $13.74
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 2.08MG | 30 Tablets | $399.51 | $13.32 |
| 2.08MG | 90 Tablets | $1,236.52 | $13.74 |
What is Zontivity used for?
Zontivity is used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with a history of heart attack or with peripheral arterial disease. It works by inhibiting platelet aggregation, which helps prevent blood clots.
What is the mechanism of action of Zontivity?
Zontivity (vorapaxar) works by inhibiting the protease-activated receptor-1 (PAR-1) on platelets. This action prevents thrombin-induced platelet aggregation, thereby reducing the risk of thrombotic cardiovascular events.
What class of drug is vorapaxar?
Vorapaxar is classified as a protease-activated receptor-1 (PAR-1) antagonist. It is used to reduce the risk of thrombotic cardiovascular events.
Is vorapaxar FDA approved?
Yes, vorapaxar is FDA approved. It was approved by the U.S. Food and Drug Administration for use in reducing thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease.
What is the indication of Zontivity?
Zontivity is indicated to reduce the risk of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease.